Abstract
This review summarizes the current knowledge on prevalence, diagnosis, prognosis and treatment in heart failure with preserved left ventricular ejection fraction. Prevalence of heart failure in Europe is increasing and at least 50% of patients with heart failure have preserved left ventricular ejection fraction.
Mechanisms and patofyziology of heart failure with preserved ejection fraction is not fully elucidated. These patients have poor long-term prognosis.
Therapy is symptomatic. Currently, no drug is available to improve prognosis.